Chapter 17: Second generation HPV vaccines to prevent cervical cancer

Détails

ID Serval
serval:BIB_CFF06A93809C
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Chapter 17: Second generation HPV vaccines to prevent cervical cancer
Périodique
Vaccine
Auteur⸱e⸱s
Schiller  J. T., Nardelli-Haefliger  D.
ISSN
0264-410X (Print)
Statut éditorial
Publié
Date de publication
08/2006
Volume
24 Suppl 3
Pages
S147-53
Notes
Journal Article --- Old month value: Aug 21
Résumé
Prophylactic human papillomavirus (HPV) vaccines based on intramuscular injection of non-infectious L1 virus-like particles (VLPs) are undergoing intense clinical evaluation. As documented in preceding chapters of this monograph, clinical trials of these vaccines have demonstrated their safety and high efficacy at preventing type-specific persistent cervical HPV infection and the development of type-specific cervical intraepithelial neoplasia (CIN) cervical neoplasia. There is widespread optimism that VLP vaccines will become commercially available within the next few years. The prospects for development of alternative HPV vaccines must be considered in light of the likelihood that a safe and effective prophylactic HPV vaccine will soon be available. Three questions need to be addressed: (1) Is there sufficient need for a second generation vaccine? (2) Are there sufficiently attractive candidates for clinical trials? (3) Is there a realistic development/commericialization path?
Pubmed
Web of science
Création de la notice
25/01/2008 14:35
Dernière modification de la notice
20/08/2019 15:50
Données d'usage